<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04573998</url>
  </required_header>
  <id_info>
    <org_study_id>LCN2</org_study_id>
    <nct_id>NCT04573998</nct_id>
  </id_info>
  <brief_title>Study on the Mechanism of lcn2 in Obesity</brief_title>
  <official_title>Study on the Mechanism of lcn2 in Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shen Qu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai 10th People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity is now becoming a worldwide serious problem. Obesity is associated with a spectrum of&#xD;
      severe diseases, including diabetes, cardiovascular diseases, and cancers. Lipocalin 2&#xD;
      (LCN2), also known as neutrophil gelatinase associated lipocalin (NGAL), is a member of the&#xD;
      lipocalin family. Due to its upregulated expression in infection, LCN2 is originally&#xD;
      considered to be a key regulator of immune response. Subsequent investigations revealed that&#xD;
      LCN2 is expressed in many tissues and is related to a variety of diseases, including obesity.&#xD;
      LCN2 was reported to be increased in obesity individuals. Thus, the investigators decide to&#xD;
      investigate the relationship between LCN2 and obesity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2016</start_date>
  <completion_date type="Anticipated">May 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>LCN2 level</measure>
    <time_frame>2019-2024</time_frame>
    <description>Lipocalin 2 level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>meet the criteria of metabolism in the 2017 Chinese guideline</measure>
    <time_frame>2019-2024</time_frame>
    <description>Abdominal obesity (or central obesity), male abdominal circumference ≥90cm, female abdominal circumference ≥85cm;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FBG</measure>
    <time_frame>2019-2024</time_frame>
    <description>patients with fasting blood glucose 6.1mmol/l or more</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PBG</measure>
    <time_frame>2019-2024</time_frame>
    <description>patients with 2 hour blood glucose 7.8mmol/l or more</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Obesity; Endocrine</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>LSG</intervention_name>
    <description>bariatric surgery</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        500 Patients from Shanghai Tenth People's Hospital were enrolled in this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1) age ranged from 16-65 years old, 2) BMI over 37.5kg/m2, or BMI over 32.5kg/m2 with&#xD;
        diabetes which meets the recommended cut off bariatric surgery of the Guidelines for&#xD;
        surgical treatment of obesity accompanied with or without type 2 diabetes in China.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1) secondary cause of obesity such as hypothalamic obesity, Cushing syndrome, and&#xD;
        hypophysis dysfunction, etc.,2)pregnancy or location, 3) contraindications for laparoscopic&#xD;
        surgery, such as gastrointestinal diseases of intra-abdominal infection, adhesion, etc., 4)&#xD;
        severe heart, liver and kidney dysfunction, 5) organic and systemic diseases intolerant of&#xD;
        surgery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shen Qu, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai 10th People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Le Bu, Dr.</last_name>
    <phone>(86)021-66301004</phone>
    <email>geyingjun@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shen Qu, Dr.</last_name>
    <phone>(86)021-66301004</phone>
    <email>qushencn@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Endocrinology, Shanghai Tenth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200070</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shen Qu, M.D. Ph.D</last_name>
      <phone>86-21-66302531</phone>
      <email>qushencn@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 21, 2020</study_first_submitted>
  <study_first_submitted_qc>September 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai 10th People's Hospital</investigator_affiliation>
    <investigator_full_name>Shen Qu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>lcn2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

